Boston, MA -- (SBWIRE) -- 03/14/2013 -- GlobalData has released its new PharmaPoint Drug Evaluation report, Actemra (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Actemra (tocilizumab) is a first-in-class recombinant humanized mAb of the IgG1 subclass that binds to the IL-6 receptor, thus blocking its ability to increase white blood cell production which increases joint inflammation. Also, by controlling IL-6 levels, iron levels remain in check as increased IL-6 depletes stored iron levels. In May 2012, Genentech announced that the SUMMACTA study met primary endpoints showing comparable efficacy of SC Actemra 162mg weekly compared to 8mg/kg IV of Actemra. ACR 20 was achieved in both groups by Week 24. Also, data released in June 2012, showed Actemra to be significantly more effective than Humira in a head-to-head trial; results are below in the efficacy section. Currently, Actemra is the only IL-6 inhibitor approved for the treatment of moderate to severe active RA.

View Full Report Details and Table of Contents

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Actemra including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Actemra for the top 10 countries from 2012 to 2022.
- Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy, India, China and Australia

Reasons to Get this Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Actemra performance
- Obtain sales forecast for Actemra from 2011-2022 in the US, Japan, UK, France, Germany, Spain, Italy, India, China and Australia

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market
- Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - Germany Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update